Last reviewed · How we verify
NCT05211206
IV Fluids and Post-ERCP Pancreatitis
trial testing IV fluids in ERCP in 13,000 participants. Status unknown.
31 December 2025
Quick facts
| Lead sponsor | University of Calgary |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 13,000 |
| Start date | 10 January 2022 |
| Primary completion | 31 December 2025 |
| Estimated completion | 28 February 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- IV fluids — full drug profile →
Conditions studied
- ERCP — all drugs for ERCP →
Sponsor
University of Calgary
Who can join
18 and older, any sex, with ERCP. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aggressive intravenous hydration has been shown in randomized trials to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), though studied regimens are often impractical. To date, no studies have prospectively assessed short-term (60-90 minute) aggressive hydration regimens that are feasible for outpatients undergoing ERCP and subsequent discharge. Furthermore, little is known with regard to fluid type, volume, and timing with respect to ERCP. In this study, we will aim to assess whether the amount of peri-procedural intravenous fluid administered around the time of ERCP is associated with the risk of PEP (the primary outcome).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05211206
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ERCP
Currently open trials in the same condition.
- NCT07368335 — Efficacy and Safety of a Novel ERCP Robot in the Treatment of Common Bile Duct Stone · NA · active not recruiting
- NCT07244432 — Post-ERCP Pancreatitis - Prophylactic Measures Implementation Study (PEP-PROMIS) · recruiting
- NCT07056075 — Prevention of Desaturations Using Positive Airway Pressure or Capnometry During ERCP · NA · recruiting
- NCT07071441 — Indomethacin vs Diclofenac for Preventing PEP · NA · recruiting
- NCT07130864 — Early vs Late Laparoscopic Cholecystectomy After Common Bile Duct Stones Clearance Through Ercp. · NA · recruiting
Other University of Calgary trials
Trials by the same sponsor.
- NCT06885996 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence · Phase 2 · not yet recruiting
- NCT05729503 — Effect of SPG Block for Patients With Anxiety at Electronic Dance Music Festivals · Phase 2 · not yet recruiting
- NCT07463339 — Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Cont · Phase 2 · not yet recruiting
- NCT07145645 — Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children · Phase 3 · recruiting
- NCT07280325 — Moxie Self-Management and Education Support Program · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05211206 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Calgary
- Last refreshed: 9 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05211206.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing